Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$5.2 million.

  • Enanta Pharmaceuticals' Change in Accured Expenses fell 7786.94% to -$5.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.2 million, marking a year-over-year decrease of 2131.87%. This contributed to the annual value of $58000.0 for FY2025, which is 10102.73% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Change in Accured Expenses is -$5.2 million, which was down 7786.94% from $2.4 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Accured Expenses peaked at $4.7 million during Q3 2021, and registered a low of -$6.7 million during Q4 2023.
  • Moreover, its 5-year median value for Change in Accured Expenses was $669500.0 (2023), whereas its average is -$197550.0.
  • In the last 5 years, Enanta Pharmaceuticals' Change in Accured Expenses skyrocketed by 93985.15% in 2021 and then crashed by 27787.93% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Change in Accured Expenses stood at $4.2 million in 2021, then tumbled by 256.89% to -$6.6 million in 2022, then decreased by 2.08% to -$6.7 million in 2023, then soared by 56.8% to -$2.9 million in 2024, then plummeted by 77.87% to -$5.2 million in 2025.
  • Its Change in Accured Expenses stands at -$5.2 million for Q4 2025, versus $2.4 million for Q3 2025 and $2.5 million for Q2 2025.